GDC-0973 plus vemurafenib versus vemurafenib alone in patients with unresectable stage IIIC or metastatic melanoma harboring BRAF V600 mutations To evaluate the efficacy of vemurafenib in combination with Cobimetinib, compared with vemurafenib and placebo, in previously untreated BRAFV600 mutation-positive patients with unresectable locally ad...

• Country None
• organs None
• Specialty None

Clinical Study To Evaluate the Recommended Dose, Safety, Pharmacokinetics and Efficacy of vemurafenib (RO5185426) in Paediatric Patients 12 to 17 Years Old With BRAFV600 Mutation Positive ESTUDIO PARA EVALUAR LA DOSIS RECOMENDADA Y CON SEGUIMIENTO DE LA EFICACIA, SEGURIDAD Y FARMACOCINÉTICA DE VEMURAFENIB (RO5185426) EN NIÑOS PACIENTE PEDIATRICOS DE 12 A 17 AÑOS CON MUTACIONES BRAFV600 Dose-escalation phase: To estimate the MTD and to identify the recommended dose of vemurafenib in pediatric patients aged 12 through 17 years with newly diagnosed or recurrent unresectable Stage IIIC ...

• Country None
• organs None
• Specialty None

A Study of Atezolizumab (Anti PD L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostrate Cancer After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen To evaluate the efficacy of atezolizumab/enzalutamide compared with enzalutamide alone

• Country None
• organs None
• Specialty None

A clinical study that will test whether cobimetinib plus atezolizumab and atezolizumab alone are effective and safe in patients with colorectal cancer that has spread when compared to regorafenib The primary efficacy objective for this study is to evaluate the efficacy of cobimetinib plus atezolizumab compared to regorafenib on the basis of overall survival (OS). Atezolizumab monotherapy will...

• Country None
• organs None
• Specialty None

A Study of Carboplatin plus Etoposide With or Without Atezolizumab in Patients with Untreated Extensive-Stage Small Cell Lung Cancer • To evaluate the efficacy of atezolizumab (Atezo) + carboplatin (Carb) + etoposide (Etop) compared with placebo + Carb + Etop in the intent-to-treat (ITT) population as measured by investigator-asses...

• Country None
• organs None
• Specialty None

A multi-part, clinical study testing the safety and effectiveness of cobimetinib in combination with paclitaxel as initial treatment for patients with triple-negative (HER2 negative, Estrogen receptor negative, and Progesterone receptor negative) breast cancer that has spread. Estudio clínico multietapa, para evaluar la seguridad y la eficacia de cobimetinib en combinación con paclitaxel como terapia inicial para pacientes con cáncer de mama triple negativo (Her2 negativo, receptores de estrogeno y receptores de progesterona negativo) que se ha dispersado To estimate the clinical benefit of cobimetinib + paclitaxel relative to placebo + paclitaxel, as measured by investigator-assessed PFS in patients with locally advanced or metastatic TNBC. Dete...

• Country None
• organs None
• Specialty None

A Study of Vemurafenib (RO5185426) in Comparison With Placebo as Adjuvant Therapy in Previously Untreated Patients With Adequately Resected Melanoma (BRIM 8) To evaluate the efficacy of vemurafenib adjuvant treatment administered over a 52-week period in patients with completely resected BRAFV600 mutation–positive, cutaneous melanoma, as measured by DFS

• Country None
• organs None
• Specialty None

A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non Urothelial Carcinoma of the Urinary Tract To evaluate the safety of atezolizumab

• Country None
• organs None
• Specialty None

A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors To provide long term follow-up and safety data in patients receiving Herceptin® following completion of a global Roche sponsored Herceptin® trial.

• Country None
• organs None
• Specialty None

DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL- TO-MILD ALZHEIMER’S DISEASE Efficacy:evaluate crenezumab 60 mg/kg compared with placebo when admin. by IV infusion q4w over 100 wks as measured(final outcome assessment at Wk 105,4 wks after the final dose)Change from baseline o...

• Country None
• organs None
• Specialty None